web analytics
10.4 C
Munich
Monday, October 25, 2021

Regen BioPharma Inc (OTCMKTS: RGBP) Biotech Sleeper Sitting on a Major League Patent Portfolio

Regen BioPharma Inc (OTCMKTS: RGBP) is easily among the most exciting stocks in small caps that has emerged in recent months as one of the most talked about and searched for stocks in the OTC. Currently under heavy accumulation RGBP has been attracting some pretty heavy hitters who see big things in the works here. The stock has a history of explosive moves running to $0.175 earlier this year after the Company and its subsidiary KLS entered into an agreement with Oncology Pharma, Inc. whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021. RGBP recently broke south of support at $0.013 briefly before heading north off support levels with power signaling to investors the next leg up is upon us. A break over $0.175 and its blue skies ahead for RGBP 

Microcapdaily has reported on RGBP many times before noting on June 14: After a brief respites RGBP is making a power house move move up the charts again looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars. RGBP is in beast mode right now and is the most talked about small cap stock; a break over $0.082 and its blue skies ahead. RGBP buyout rumors abound; according to many investors It appears there may be a Potential Merger Acquisition looming with Precigen OR another Big Pharma and if so it would make perfect sense for the following reasons. The CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $1.3B and has an extensive clinical trials pipeline in Immunology-Oncology that includes development of mRNA vaccines therapies. https://precigen.com/about. Regenis in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that RGBP is in. 100% identical including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP OR does a Merger Acquisition and IMO the motive to do this are the numerous valuable Patents RGBP owns that have Billion Dollar Market Capacity. Koos is presently on an aggressive campaign to pull everything together about RGBP in the shortest amount of time to apparently ready the company for SALE! If you look closely at his recent actions it points to this. 

PictureRegen BioPharma Inc (OTCMKTS: RGBP) is a publicly traded biotechnology company focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). RGBP owns a valuable patent porfolio.

PictureThe Company is led by CEO David Koos who has over 30 years of investment banking and venture capital experience.  He has a deep knowledge of startup businesses, public markers and SEC reporting companies.  Dr. Koos has extensive relationships with large and small financial institutions, hedge funds and entities that Regen BioPharma expects to leverage for company growth. Dr. Koos has a Ph.D. in Sociology and a Doctor of Business Administration with an emphasis in finance.  Additionally, he has authored / coauthored  numerous peer reviewed journal articles. Dr. Koos has been working hard behind the scenes getting all the filings into OTC Markets Group in order to go “pink current” 

RGBP owns a valuable patent porfolio. Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses. The Company’s products include HemaXellerate, a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning. HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow  Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS. The United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376) 

dCellVax Breast Cancer – dCellVax – IND #16200. CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.” Establishment of safety will allow for rapid expansion of patient numbers. Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program. 

DiffronC – Myelodysplastic Syndrome Gene Silencing – DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells. Silencing using DiffronC induces differentiation of cancer cells. Initial indication is treatment of myelodysplastic syndrome. Other indications include solid tumors and acute leukemia. 

Telomeres & Genomic Integrity: Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres. Telomeres are protective structures at the ends of chromosomes that enable cell divisions. Telomere attrition is involved in aging, cancer and genetic mutations. The Company is developing drugs that modulate telomere maintenance. In pre-clinical development for indications of solid cancers and acute leukemia. 

In the CBD space RGBP researchers have determined that combining its lead NR2F6 small molecule agonist with Cannabidiol (CBD) may provide a dynamic therapy for treating inflammatory bowel disease (IBD). Currently, there are a number of pre-clinical and clinical studies being conducted by other companies regarding pain management that suggest potential benefits of CBD. Regen believes that CBD may augment the Company’s small molecule therapies for autoimmune disorders, in this case specifically IBD. IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn’s disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA. The IBD market size is estimated at $6.7 billion global and projected to be $7.6 billion by 2023.There are currently no non-steroidal therapies available to IBD sufferers. 

Let’s objectively review what that is: 

1). on 4/8/21 he files an 8K which in and of itself is a dead give-a-away of what he’s up to. The question begs why would he file an 8K that specifically gives himself exclusive control of voting rights in negotiations for the sale of the company during the bidding process that’s specifically intended to prevent a Hostile Take Over? And in doing this he states quote: “persons of interest who want to ACQUIRE RGBP must negotiate directly.” This is in reference to himself having sole control of voting rights that this 8K gives him. Other words, negotiations for sale of the company can’t go around him to his board which is a typical move in any hostile take over. This by itself reveals what he’s up to in addition to MANY other factors shown below. https://sec.report/Document/0001607062-21-000145/ 

2). he recently hired a Firm to get OTC current with FULL disclosure reporting. This has to do not only with SEC compliance to remain listed on the OTC beyond September 2021 but ALSO it provides transparency for any potential Big Pharma buyers that would never consider buying a company otherwise. 

3). on 6/1/21 he files another 8K that has to do with resolving a lawsuit. This would be important to any potential buyers for reason a pending unresolved lawsuit would likely complicate negotiations of a buy out, or it would be a deterrent altogether. https://sec.report/Document/0001607062-21-000145/ 

4). we see him moving to get all his expired Patents updated. Logically this move would be consistent with preparing for an acquiring company to take over the patents then turn around and file an FDA IND post buy out in order to immediately place those candidate drug Patents in their clinical trials pipeline. 

5). lastly he’s not updating the company website that’s been outdated for years. Why would he invested time, energy, and money in updating his company website if he’s about to sell the company? 

On April 7, 2021 KCL Therapeutics, Inc. (“KCL”) (RGBP subsidiary) entered into an agreement with Oncology Pharma, Inc. whereby KCL granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021. 

As consideration to KCL for the rights and license granted pursuant to the Agreement Licensee shall: pay to KCL a nonrefundable fee of Fifty Thousand common shares of Oncology Pharma, Inc. no later than April 20,2021, pay to KCL royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter. pay to KCL ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which KCL receives payment. ONCP is trading at $33 at an $847 million market valuation, the 50,000 shares are worth $1,500,000) 

To Find out the inside Scoop on RGBP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RGBP

RGBP

RGBP filed an 8k reporting that on July 8 BF Borgers CPA PC; Regen Biopharma Inc.’s independent registered public accounting firm, began the audit of financial statements for the fiscal year ended September 30, 2020 required to be included in Regen’s Annual Report for the fiscal year ended September 30, 2020 to be filed with the United States Securities and Exchange Commission on Form 10-K. Regen’s financial statements for the fiscal years ended September 30, 2019 and September 30, 2018 (included in the Company’s Annual report for the fiscal year ended September 30, 2019 filed on Form 10-K) had also been audited by Borgers. The commencement of this audit of the Company’s financial statements is a further step taken by the Company towards curing the Company’s delinquency with regard to periodic reports required to be filed with the United States Securities and Exchange Commission. 

On July 13 RGBP filed an 8k listing the Company’s issued patents and pending patents:

  1. GENE SILENCING OF THE BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS): Patent No: 8263571
  2. METHODS AND MEANS OF GENERATING IL-17 ASSOCIATED ANTITUMOR EFFECTOR CELLS BY INHIBITION OF NR2F6 INHIBITION: PatentNo :11,053,503 
  3. METHODS OF SCREENING COMPOUNDS THAT CAN MODULATE NR2F6 BY DISPLACEMENT OF A REFERENCE LIGAND: Patent No: 10,088,485
  4. MODULATION OF NR2F6 AND METHODS AND USES THEREOF: Patent No: 9091696

IP for which a Notice of Allowance has been granted. A Notice of Allowance is notification by the USPTO to the applicant that the USPTO intends to issue a patent 

  1. ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES: Application Number: 15/162,370

IP for which Patent Protection has expired due to non payment of fees for which revival is in process: 

  1. METHOD OF CANCER TREATMENT USING SIRNA SILENCING Patent No: 8389708

IP for which a Notice of Allowance was granted but classified as abandoned by the USPTO. Revival in progress. 

  1. UNIVERSAL DONOR CHECKPOINT INHIBITOR SILENCED/GENE EDITED CORD BLOOD KILLER CELLS: Application Number: 15/494,358

Active Patent Applications: 

  1. ENHANCED DENDRITIC CELL IMMUNE ACTIVATION BY COMBINED INHIBITION OF NR2F6 WITH CANNIBIDIOL; Application Number 17035955.
  2. REDUCTION OF POST-SURGERY CANCER METASTASIS BY COMBINATION OF CANNABIDIOL AND NR2F6 INHIBITION. Application Number 17037284
  3. SUPPRESSION OF PATHOLOGICAL ANGIOGENESIS BY INHIBITION OF NR2F6 Application Number 17087386
  4. STIMULATION OF T REGULATORY CELLS BY CANNABIDIOL AS A MEANS OF TREATING ARTHRITIS AND AUTOIMMUNITY Application Number 17010720
  5. SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN HUMANS Application Number 15820324
  6. SMALL MOLECULE MODULATORS OF NR2F6 ACTIVITY. Application Number 15364111

Patent issued to Zander Therapeutics, Inc. derived from intellectual property licensed by Zander Therapeutics Inc. from KCL. 

  1. CANINE AUTOLOGOUS IMMUNOTHERAPY USING DENDRITIC CELL INDUCED CANCER KILLING IMMUNOCYTES: Patent Number: 10,030,227

 For more on RGBP Subscribe Right Now!

RGBP is easily among the most exciting stocks in small caps that has emerged in recent months as one of the most talked about and searched for stocks in the OTC. Currently under heavy accumulation RGBP has been attracting some pretty heavy hitters who see big things in the works here. The stock has a history of explosive moves running to $0.175 earlier this year after the Company and its subsidiary KLS entered into an agreement with Oncology Pharma, Inc. whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021. RGBP recently broke south of support at $0.013 briefly before heading north off support levels with power signaling to investors the next leg up is upon us. A break over $0.175 and its blue skies ahead for RGBP  Microcapdaily has reported on RGBP many times before noting on June 14: After a brief respites RGBP is making a power house move move up the charts again looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars. RGBP is in beast mode right now and is the most talked about small cap stock; a break over $0.082 and its blue skies ahead. RGBP buyout rumors abound; according to many investors It appears there may be a Potential Merger Acquisition looming with Precigen OR another Big Pharma and if so it would make perfect sense for the following reasons. The CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $1.3B and has an extensive clinical trials pipeline in Immunology-Oncology that includes development of mRNA vaccines therapies. https://precigen.com/about. Regenis in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that RGBP is in. 100% identical including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP OR does a Merger Acquisition and IMO the motive to do this are the numerous valuable Patents RGBP owns that have Billion Dollar Market Capacity. Koos is presently on an aggressive campaign to pull everything together about RGBP in the shortest amount of time to apparently ready the company for SALE! If you look closely at his recent actions it points to this. We will be updating on RGBP when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with RGBP.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in RGBP either long or short and we have not been compensated for this article

More articles

3 COMMENTS

  1. Regen BioPharma Inc (OTCMKTS: RGBP) has almost 4 billion shares Outstanding. Looks like an ATM machine cash cow !

    This stock does NOT have Current Pink information . Beware September 28th.

    Status Active
    Market Cap $ 51,202,752
    Shares Authorized 4,800,000,000
    Shares Outstanding 3,780,195,788

    Company Info
    Ticker Symbol USOTC:RGBP
    OTC Market Pink No Information
    Security Type Common Stock
    CIK Number 0001589150

  2. Why no update on $RGBP? It has gone current and yet the stock continues to tank. Are you guys not going to try and pump this any more? Please, you need to as there are so many bag holders that want to get their money back and only you guys can pump this back up!

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.